GlassScriptPhysician profile
Tiffany Hong
NPI 1528445459
$9,392.47
in general payments reported to CMS, 2019-2025
28 companies · $4,095 in 2025
The $4,095 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.89 · 2020: $19.74 · 2021: $491 · 2022: $528 · 2023: $482 · 2024: $3,710 · 2025: $4,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,000 · Food and Beverage: $1,202 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,000.00 |
| Food and Beverage | $1,201.54 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $7,000.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $361.02 | 2019-2023 | |
| Astellas Pharma US INC | $350.91 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $179.12 | 2022-2024 | Injectafer |
| Mayne Pharma Commercial LLC | $178.70 | 2022-2025 | |
| Sage Therapeutics, LLC | $145.56 | 2021-2025 | Zurzuvae |
| Organon LLC | $128.32 | 2021-2025 | Nexplanon |
| Roche Diagnostics Corporation | $103.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.19 | 2022-2025 | |
| Applied Medical Resources Corporation | $86.01 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $85.04 | 2022 | |
| Minerva Surgical, INC | $74.59 | 2022-2023 | |
| Exeltis, USA INC. | $70.85 | 2020-2025 | Slynd |
| Ethicon US, LLC | $68.56 | 2019-2024 | Surgicel Nu-Knit, Dermabond Prineo, Vistaseal |
| Hologic Sales and Service, LLC | $66.24 | 2023-2024 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $65.53 | 2025 | Myfembree |
| Therapeuticsmd, INC. | $56.81 | 2021-2022 | |
| Coopersurgical, INC. | $56.18 | 2023-2025 | Paragard T 380a |
| Dilon Technologies, INC. | $39.25 | 2025 | Hemoblast Bellows |
| Merck Sharp & Dohme LLC | $38.17 | 2019-2021 | |
| Avanos Medical | $26.47 | 2021 | |
| Avion Pharmaceuticals | $20.14 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.69 | 2024 | |
| Millicent US INC | $17.64 | 2024 | Femring, Intrarosa |
| Pfizer INC. | $16.94 | 2024 | |
| Kci USA, INC. | $14.83 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.78 | 2021 | |
| Meditrina | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.